Production (Stage)
Kyverna Therapeutics, Inc.
KYTX
$3.39
$0.4515.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 11.80% | 14.70% | |||
| Gross Profit | -11.80% | -14.70% | |||
| SG&A Expenses | -3.70% | 31.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.14% | 18.27% | |||
| Operating Income | -8.14% | -18.27% | |||
| Income Before Tax | -19.06% | -8.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.06% | -8.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.06% | -8.69% | |||
| EBIT | -8.14% | -18.27% | |||
| EBITDA | -7.80% | -18.41% | |||
| EPS Basic | -19.10% | -8.51% | |||
| Normalized Basic EPS | -10.82% | -22.66% | |||
| EPS Diluted | -19.10% | -8.51% | |||
| Normalized Diluted EPS | -10.82% | -22.66% | |||
| Average Basic Shares Outstanding | -0.04% | 0.18% | |||
| Average Diluted Shares Outstanding | -0.04% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||